Studiengesellschaft BSF UG (haftungsbeschraenkt)
- Address
- Grosse Nikolaistrasse 7, Altstadt, 06108 Halle, Germany
Digestive System Diseases
At Studiengesellschaft BSF UG (haftungsbeschraenkt) in Halle (Saale), much of the research focuses on digestive system diseases, especially Crohn’s disease, ulcerative colitis, and celiac disease. These studies are designed to test new treatments, compare therapeutic options, and better understand how to improve symptom control and intestinal healing.
- Testing targeted therapies for moderate to severe Crohn’s disease and ulcerative colitis
- Evaluating treatment effectiveness for fibrostenotic Crohn’s disease and other difficult-to-manage forms
- Assessing new approaches for celiac disease and gluten-related intestinal damage
Overall, the site is active in research aimed at improving both short-term disease control and longer-term outcomes for people living with chronic gastrointestinal conditions.
Immune System Diseases
This site also contributes to studies in immune system diseases, with a strong link to inflammatory conditions that affect the gut. The research commonly examines how immune-targeted therapies can reduce inflammation, support remission, and improve quality of life for patients with ongoing immune-mediated illness.
- Exploring immune-modulating therapies for inflammatory bowel disease
- Studying how new treatments affect inflammation and mucosal recovery
- Assessing whether combination strategies can improve disease control
These trials reflect a broader effort to refine treatment choices for chronic immune-driven disorders, with an emphasis on safer and more effective care.
Neoplasms
Research in neoplasms at the site includes studies in colorectal cancer and gastric or gastroesophageal junction adenocarcinoma. The main goal is to evaluate whether newer treatment strategies can improve disease-free survival, slow progression, and strengthen first-line cancer care.
- Investigating treatment strategies for stage II and stage III colorectal cancer
- Evaluating therapy for metastatic gastric and gastroesophageal junction cancer
- Comparing new cancer approaches with standard monitoring or existing regimens
These oncology studies focus on improving outcomes for patients with advanced or high-risk cancers through better treatment effectiveness and disease control.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Janssen Cilag International4active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International8trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Studiengesellschaft BSF UG (haftungsbeschraenkt)
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2a, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AGMB-129 in Patients with Fibrostenotic Crohn’s Disease | Agomab Spain S.L.U. | Phase II | Not Recruiting | Nov 2023 | Jun 2026 |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 6 | Unknown | 2019-10-19 | 2024-11-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.